A coding single nucleotide polymorphism in the interleukin-6 receptor enhances IL-6 signalling in CD4 T cells and predicts treatment response to tocilizumab in giant cell arteritis
Annals of the Rheumatic Diseases · 2025
DOI: 10.1016/j.ard.2025.01.049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2025. Verfasst von Robert Zorc und 21 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Receptors, Interleukin-6, Giant Cell Arteritis, Interleukin-6. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
OBJECTIVES: The study objective was to determine if a common single nucleotide polymorphism in the interleukin 6 (IL-6) receptor (rs2228145, p.Asp358Ala) predicted treatment response to tocilizumab in giant cell arteritis (GCA). METHODS: Genetic sequencing of the rs2228145 locus was performed in 2 independent cohorts of patients with GCA. Peripheral blood mononuclear cells (PBMCs) from patients and controls were evaluated for expression of the interleukin 6 receptor (IL-6R) and its coreceptor, gp130, using flow cytometry. The same PBMCs were stimulated with IL-6 and evaluated for downstream targets of IL-6: STAT3 phosphorylation (pSTAT3) and IL-17A expression. RESULTS: In total, 100 patients with GCA were included (derivation cohort n = 58; validation cohort n = 42). The rs2228145 variant predicted tocilizumab response in each cohort. In the derivation cohort, a gene dose-dependent response was observed with a 36% response rate in the homozygous patients and 95% response rate in patients without the variant (P = .003). In the validation cohort, tocilizumab response rates were 50% for homozygotes and 85% for patients without the variant (P = .04). pSTAT3 levels were significantly increased in response to IL-6 stimulation in a gene dose-dependent manner in CD4 T cells from patients with GCA but not controls. CD4 T cells from patients with GCA had significantly higher membrane expression of gp130 than healthy controls, and response to IL-6 correlated with gp130 expression. IL-17 producing CD4 T cells were increased in a gene dose-dependent response to IL-6 (P < .01). CONCLUSIONS: The rs2228145 variant is associated with decreased treatment response to tocilizumab and worse outcomes in GCA by enhancing CD4 T cell response to IL-6.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
- Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, MD, USA.
- Department of Medicine, Vanderbilt University, Nashville, TN, USA.
- Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA; Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Me…
Förderung
- Intramural NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Heart, Lung, and Blood Institute
- National Institutes of Health
Zitieren
APA
Zorc, R., Redmond, C., Sylvester, M., Maclean, M., Yamamoto de Almeida, L., Quinn, K. A., Tomelleri, A., Campochiaro, C., Dagna, L., Gutierrez-Rodrigues, F., Wells, K. V., Rankin, C., Hait, S. H., Palmer, C., Corty, R., Bick, A., Lambert, K., Buckner, J. H., O'Shea, J. J., …, & Grayson, P. C. (2025). A coding single nucleotide polymorphism in the interleukin-6 receptor enhances IL-6 signalling in CD4 T cells and predicts treatment response to tocilizumab in giant cell arteritis. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.01.049
Vancouver
Zorc R, Redmond C, Sylvester M, Maclean M, Yamamoto de Almeida L, Quinn KA, et al. A coding single nucleotide polymorphism in the interleukin-6 receptor enhances IL-6 signalling in CD4 T cells and predicts treatment response to tocilizumab in giant cell arteritis. Annals of the Rheumatic Diseases. 2025. doi:10.1016/j.ard.2025.01.049
BibTeX
@article{Zorc2025,
author = {Zorc, Robert and Redmond, Christopher and Sylvester, McKella and Maclean, Mary and Yamamoto de Almeida, Luciana and Quinn, Kaitlin A and Tomelleri, Alessandro and Campochiaro, Corrado and Dagna, Lorenzo and Gutierrez-Rodrigues, Fernanda and Wells, Kristina V and Rankin, Cameron and Hait, Sabrina Helmold and Palmer, Chloe and Corty, Robert and Bick, Alexander and Lambert, Kathi and Buckner, Jane H and O'Shea, John J and Park, Jin Kyun and Gadina, Massimo and Grayson, Peter C},
title = {A coding single nucleotide polymorphism in the interleukin-6 receptor enhances IL-6 signalling in CD4 T cells and predicts treatment response to tocilizumab in giant cell arteritis},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
doi = {10.1016/j.ard.2025.01.049}
}
EUVIMED